PFE logo

Pfizer Stock Price

Symbol: NYSE:PFEMarket Cap: US$133.8bCategory: Pharmaceuticals & Biotech

PFE Share Price Performance

US$24.75
-4.57 (-15.59%)
31.5% undervalued intrinsic discount
US$36.12
Fair Value
US$24.75
-4.57 (-15.59%)
31.5% undervalued intrinsic discount
US$36.12
Fair Value
Price US$24.75
AnalystHighTarget US$36.12
AnalystConsensusTarget US$28.67
AnalystLowTarget US$24.57

PFE Community Narratives

AN
AnalystHighTarget
AnalystHighTarget·Updated
Fair Value US$36.12 31.5% undervalued intrinsic discount

Next-Gen Biologics And AI Will Tap Global Aging Trends

2users have liked this narrative
0users have commented on this narrative
24users have followed this narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget·Updated
Fair Value US$28.67 13.7% undervalued intrinsic discount

R&D And Oncology Programs Will Shape Future Success

5users have liked this narrative
1users have commented on this narrative
428users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget·Updated
Fair Value US$24.57 0.8% overvalued intrinsic discount

Paxlovid And Vyndaqel Will Fall And Readouts Will Deliver Hope

0users have liked this narrative
0users have commented on this narrative
15users have followed this narrative

PFE Community Fair Values

Recent PFE News & Updates

No updates

Pfizer Inc. Key Details

US$63.8b

Revenue

US$16.4b

Cost of Revenue

US$47.5b

Gross Profit

US$36.7b

Other Expenses

US$10.7b

Earnings

Last Reported Earnings
Jun 29, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
1.89
Gross Margin
74.36%
Net Profit Margin
16.81%
Debt/Equity Ratio
69.4%

Pfizer Inc. Competitors

 
 
 
 
 
 
 
 
 
 
 
 

About PFE

Founded
1849
Employees
81000
CEO
Albert Bourla
WebsiteView website
www.pfizer.com

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Octagam, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

U.S. Market Performance

  • 7 Days: -1.2%
  • 3 Months: 12.3%
  • 1 Year: 21.3%
  • Year to Date: 7.0%
In the last week, the market has fallen 1.2%, dragged down most by the Consumer Discretionary. As for the longer term, the market has actually risen by 21% in the last year. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading